Abstract: The present invention relates to an intracellular expression enhancing genetic element, which enhances the intracellular expression of target protein encoded in RNA therapeutics such as mRNA vaccines and RNA medicines. In more detail, the present invention relates to the RNA molecule which has the genetic element capable of enhancing the intracellular expression of target protein encoded in RNA therapeutics delivered into cells; the plasmid used to synthesize the RNA molecule having the genetic element “E3”; the method for synthesizing RNA molecule having the genetic element “E3” using the plasmid and utilizing the synthesized RNA molecule as RNA therapeutics.

Abstract: An apparatus for manufacturing a secondary battery includes: an index table configured to receive a secondary battery cell, the secondary battery cell including an electrode assembly, a can accommodating the electrode assembly, and an electrode tab between the electrode assembly and the can to electrically connect the electrode assembly to the can; a laser scanner configured to irradiate laser onto an outer surface of the can to weld the electrode tab to the can; and a controller configured to variably control the laser scanner according to an operation of the index table.

Abstract: A gripper includes a body part, a finger base part coupled to the body part, and a finger part coupled to a first side of the body part or the finger base part and coupled to the body part or the finger base part to be reciprocal, wherein the finger part comprises a first link structure and a second link structure, sides of which are coupled to the finger base part, respectively, and wherein, in the first link structure and the second link structure, a first support area of the first link structure and a second support area of the second link structure reciprocate in only one of a plurality of directions that cross a direction in which the finger part reciprocates with respect to the finger base part.

Abstract: A gripper includes a body part, a finger base part coupled to the body part to be rotatable, the finger base part including a first finger base part and a second finger base part configured such that when the first finger base part is rotated in a first direction with respect to the body part, the second finger base part is provided to be rotatable in a second direction opposite the first direction with respect to the body part, and a finger part coupled to a first side of the body part or the finger base part to be reciprocal.

Abstract: Disclosed are a separator for fuel cells capable of minimizing the volume of a system and the use of sealants, and a stack for fuel cells, more particularly, a stack for solid oxide fuel cells, including the same. Specifically, by adding a metal sheet having a specific shape, position and size to the separator, the stress applied to the sealant can be uniformized, and thus the oxidizing agent and fuel can be separated and electrically isolated using only a piece of sealant. Therefore, the stack for fuel cells is characterized in that there is no variation in temperature, reactant concentration, power, or the like between respective unit cells, so delamination and microcracks do not occur, the volume is minimized, and the power density per unit volume is very high.

Abstract: An embodiment device includes an input module including a motor configured to generate a rotational force, an output module configured to receive power from the input module to be rotatable, and a connection module having a first side coupled to the input module and a second side, opposite the first side, coupled to the output module, wherein the connection module is configured to transmit the power from the input module to the output module.

Abstract: An embodiment joint structure includes a first connection link configured to be fixed to one side of a wearer, a second connection link coupled to the first connection link to be rotatable about a first rotation axis, a third connection link coupled to the first connection link to be rotatable about a second rotation axis spaced apart from the first rotation axis, and a fourth connection link, a first side of which is coupled to the second connection link to be rotatable about a third rotation axis and a second side of which is coupled to the third connection link to be rotatable about a fourth rotation axis spaced apart from the third rotation axis, wherein an imaginary first extension axis, an imaginary second extension axis, an imaginary third extension axis, and an imaginary fourth extension axis intersect each other in an intersection area.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.

Abstract: A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the porcine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the porcine myoglobin prepared in accordance with the method.

Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.

Abstract: An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.

Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.

Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.

Abstract: The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.

Abstract: A method for preparing a soy leghemoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing gene for Glycine max leghemoglobin LGB2; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the soy leghemoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the soy leghemoglobin prepared in accordance with the method.

Abstract: A method for preparing a bovine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Bos taurus myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the bovine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the bovine myoglobin prepared in accordance with the method.

Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.